The safety and efficacy of three different dosing schedules of the CTLA-4 inhibitor ipilimumab and nivolumab was evaluated in advanced HCC following prior sorafenib treatment at three different doses: nivolumab (1 mg/kg) + ipilimumab (3 mg/kg) or nivolumab (3 mg/kg) + ipilimumab (1 mg/kg) every 3 weeks for four doses followed by nivolumab maintenance (240 mg flat dose every 2 weeks), and nivolumab (3 mg/kg) + ipilimumab (1 mg/kg) every 6 weeks, until disease progression or toxicity. Here, CTLA4 is linked to hepatocellular carcinoma.